Skip to content Skip to left sidebar Skip to footer

COVID-19 Vaccine

COVID Weekly Reporting Beginning May 1

Weekly Reporting Beginning May 1

UPDATE: As of May 1, 2022, providers are only required to report COVID-19 vaccine supply levels at least weekly by close of business on Fridays. Daily reporting of inventory to VaccineFinder is no longer required. All other requirements regarding data reporting, to the IIS for example, remain unchanged.

We appreciate your efforts to update data in VaccineFinder. If your site does not have access to VaccineFiner or needs to change the primary or backup contact for VaccineFinder, please reach out to covidproviders@phila.gov. Please note that only two individuals can receive registration links for VaccineFinder. In some instances, sites may only be able to have one individual reporting to VaccineFinder depending on how the account was initially setup.

Pfizer Tris Shelf Life Extension (9-12 Months) Approved

Pfizer Tris Shelf Life Extension (9-12 Months) Approved

The Food & Drug Administration has approved an amendment to the EUA for Pfizer Tris COVID-19 vaccine extending the shelf-life of the following Pfizer product formulations from 9 to 12 months:

  • Pfizer Tris Pediatric vaccine (Orange Cap for ages 5 through 11, with diluent)
  • Pfizer Adult Tris (Gray Cap for ages 12+, no diluent)

Vials stored consistently in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F) may remain in use for up to 12 months beyond the date of manufacture printed on the vials and cartons. Vials stored in refrigerated vials (2°C to 8°C) are NOT eligible for extension, regardless of the expiration date. Additional information on Pfizer storage and handling may be found at Administration Overview for Pfizer-BioNTech COVID-19 Vaccine | CDC.

Pfizer Orange and Gray Cap Tris Vaccine expiry dates based on 12 months from the date of the manufacture are shown below and at Expiry Information for Pfizer COVID-19 Vaccines.

No changes have been made to the vaccine itself to enable extension of expiry dating. This change is based on stability data submitted by the manufacturer to the FDA.

Reminders:

  • Do not use Pfizer Tris products beyond 12 months from manufacture date.
  • Expiration dates for the Pfizer TRIS products are NOT printed on the vaccine cartons or vials.
  • Do not store Pfizer vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed, they should not be refrozen.

For more information, please review the updated FDA Factsheets:
Fact Sheet for Healthcare Providers Administering Vaccine (Gray Cap/Adult)
Fact Sheet for Healthcare Providers Administering Vaccine (Orange Cap/PEDS)

COVID-19 vaccines authorized under an EUA do not have fixed expiration dates, and expiration dates may be extended as more stability data is collected. Always check Expiry Information for Pfizer COVID-19 Vaccines  to obtain the most up-to-date expiration dates for the Pfizer COVID-19 vaccines you have in inventory.

COVID-19 Vaccine Ordering Guidance

COVID-19 Vaccine Ordering Guidance

When providers are ordering in Philavax, please keep in mind that there are “Minimum Order Quantities.” This means that if you place an order below the minimum order quantity, PDPH will automatically increase it to meet the requirement. See table below for the MOQ’s (minimum order quantities) for each vaccine.

A couple of things to note:

  • Pfizer gray cap must be ordered in increments of 300 doses in Philavax which is a total of 5 boxes.
  • Janssen has to be ordered in increments of 100 doses in Philavax which is a total of 2 boxes.
    • The Food & Drug Administration announced the approval of a shelf-life extension for the J&J/Janssen COVID-19 vaccine for an additional two months. The shelf-life of this vaccine has been updated from 9 months to 11 months.

Partial Orders/Small Quantity Orders
If your site is interested in receiving less than the minimum order quantity (i.e., a couple of vials), you can place an order in Monday.com. All vaccine orders placed via Monday.com will arrive refrigerated on the following Tuesday or Wednesday. You can place a note in the comment section if you need to order Janssen or Moderna vials. Please do not forget to submit a temperature log and reconciliation with Monday.com orders. These orders are due by Wednesday at 5pm as well.

Place a partial order.

Communicating About Vaccines: COVID-19 & More

Communicating About Vaccines: COVID-19 & More

The Philadelphia Department of Public Health recently collaborated with Children’s Hospital of Philadelphia to develop a new educational module, “Communicating about Vaccines – COVID-19 & More.”

This free, web-based interactive session offers a two-hour training divided into three parts:

  1. Details the dangers of COVID-19 disease, explains the U.S. system to authorize and approve vaccines, and highlights the safety & effectiveness of COVID-19 vaccines.
  2. Explores best practices in vaccine communication.
  3. Reviews the module, offers additional resources, and explains how to receive continuing education credit or a certificate of attendance.

To learn more about the module or access continuing education credits (a version with no credits is also available), visit chop.edu/vaccine-online-learning.

This module was developed for adult and pediatric providers, immunization champions, and community members. It provides an understanding of COVID-19 disease, how the vaccine approval process works, and how to communicate effectively about these topics, so that ultimately stakeholders — and their constituents — have a solid, or reinforced, urgency regarding what the receipt of vaccines can do to protect people from COVID-19.

Please consider sharing with your colleagues and partners. If you have feedback or questions, email vacinfo@chop.edu using the subject line “COVID-19 online modules.”

Development of this free module was led and supported by the Vaccine Education Center and the Office of Community Engagement at the Children’s Hospital of Philadelphia, in partnership with the Pennsylvania Chapter, American Academy of Pediatrics, Pennsylvania Immunization Coalition, and Philadelphia Department of Public Health.

COVID-19 Ancillary Kit Update

COVID-19 Ancillary Kit Update

All Moderna COVID-19 vaccine shipments will now include only one ancillary kit: one ancillary kit to one carton of vaccine, instead of two ancillary kits to one carton of vaccine. This change will take effect with orders placed beginning on Monday, April 11, 2022, at 10 am ET.

Providers are able to opt-out of future ancillary kit shipments (with the exception of Pfizer 5-11, as it requires diluent). In order to do so, please place a note in the comment section of your order if you are interested in opting out of Moderna, Janssen, and Gray Cap Pfizer supplies.

Although many providers are reporting an excess of ancillary supplies, PDPH is unable to accept any ancillary kits/supplies back from providers. Ancillary supplies can be donated domestically (not internationally) if sites are unable to use them. However, surplus CDC cards should be properly destroyed to avoid any misuse. If disposing of any needles, providers should utilize the appropriate sharps bins.

Email COVID@phila.gov with any questions.

HRSA Has Stopped Accepting COVID-19 Uninsured Claims

HRSA Has Stopped Accepting COVID-19 Uninsured Claims

CDC strongly encourages providers to continue administering vaccines.

Due to the lack of supplemental funding from Congress, HRSA has stopped accepting claims for reimbursement of costs associated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5, 2022.  

CDC encourages providers to stay in the CDC COVID-19 Vaccination Program and continue administering these lifesaving vaccines at no cost to patients. CDC remains committed to ensuring equitable access to COVID-19 vaccines. 

As a reminder, COVID-19 Vaccination Program providers cannot:

  • Administer COVID-19 vaccine at any out-of-pocket cost to the recipient
  • Deny anyone vaccination, or differentially reducing appointment access, based on the vaccine recipient’s coverage status or network status
  • Charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided
  • Require additional medical services to receive COVID-19 vaccination
  • Seek any reimbursement, including through balance billing, from the vaccine recipient

Where CDC becomes aware of a provider engaging in any of the following, CDC will consider taking any and all appropriate measures, including the possibility of rescinding the CDC provider agreement.

For further information, please see the CDC COVID-19 Vaccination Program Provider Requirements and Support webpage

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.

New Resource Available for In-Home COVID Vaccination Providers

New Resource Available for In-Home COVID Vaccination Providers

There is a new resource available for COVID-19 providers who are vaccinating in the home. It contains contact and website information that can be used to report and assist with commonly encountered situations. Providers are welcome to utilize this information as needed and can also reach out to PDPH if they have any additional questions about in-home vaccinations.

Resources for In-Home Vaccine Providers

These resources can be used to report and assist with commonly encountered situations.

For legal assistance when encountering domestic violence, hoarding, home repair, or neighbor disputes, please contact:

For situations involving older adults, including elder abuse/crime, homecare and residential care, caregiver information and resources, or housing, home repair, food, legal resources, and transportation, please contact:

  • Center for Advocacy for the Rights and Interests of the Elderly (CARIE): www.carie.org | 1-800-356-3606
  • Philadelphia Corporation for Aging (PCA): www.pcacares.org | 215-765-9040

For other disability specific resources:

To report suspected instances of Child Abuse, call ChildLine at 1-800-932-0313.
To report suspected instances of Human Trafficking, call the National Human Trafficking Hotline at 1-888-373-7888.

For all urgent or life threatening emergencies, dial 9-1-1.

View printable resources.

FDA Authorizes Second COVID-19 Booster Dose

FDA Authorizes Second COVID-19 Booster Dose

On March 29, 2022, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization, and death. Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns.

The agency amended the emergency use authorizations as follows:

  • A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
  • A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
  • A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.

The amendments to the EUAs to include a second booster dose for these populations were granted to Pfizer Inc. and ModernaTX Inc.

For the entire FDA press release, click here.

Emergency Use Authorizations:
Pfizer Vaccine: Pfizer-BioNTech COVID-19 Vaccine Information | CDC
Moderna: Moderna COVID-19 Vaccine Information | CDC
Janssen: Johnson & Johnson’s Janssen COVID-19 Vaccine Information | CDC

New Resources Available: Beyond-Use Date (BUD) Labels, Dose Trackers, and Storage Unit Guides

New Resources Available: Beyond-Use Date (BUD) Labels, Dose Trackers, and Storage Unit Guides

Vaccines must be maintained according to manufacturer guidelines to ensure vaccine viability. However, storing and administering multiple COVID-19 vaccine products can be confusing.

The following tools are intended to assist providers in storing, tracking BUD/expiration dates, and tracking vaccine administrations, as well as wastage. Please use the links below to access these resources.

Storage Unit Guides
BUD Labels
Dose Trackers

Janssen (J&J) Shelf-Life Extension

Johnson & Johnson’s Janssen Shelf-Life Extension


The Food & Drug Administration has approved a shelf-life extension for the Johnson & Johnson’s Janssen COVID-19 vaccine for an additional three months. The shelf-life of this vaccine has been updated from 6 months to 9 months. 

This decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 9 months when refrigerated at temperatures of 36° – 46° Fahrenheit (2° – 8° Celsius).

This shelf-life extension applies to all inventory dated to expire on March 7, 2022 or later. Vaccine dated prior to March 7, 2022 should be disposed of according to state and local regulation and reported as waste according to your COVID-19 provider agreement. 

Please refer to the current EUA fact sheet by clicking on the button below.


Vaccine providers should visit the Janssen COVID-19 Vaccine Expiry Checker webpage to confirm expiration dates. This shelf-life extension applies to refrigerated vials of J&J/Janssen COVID-19 vaccine that have been held in accordance with the manufacturer’s storage conditions.

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.